I-Mab Biopharma

NEWS & INSIGHTS (incl. Key Themes, Latest Interviews, Recent Reg. Guidance)

• Notable Theme (Commercial): Biotech companies continue to face difficult choices with access to cash constrained: speaking at Swiss Biotech Day in Basel, Sanofi's R&D chief Houman Ashrafian, who until 2023 was a biotech investor who co-founded nine companies, cautioned them nevertheless not to "squeeze clinical development", as cost-saving at the expense of decent trial data represented a "false economy”.
• Notable Theme (Commercial): Trump's effort to get pharma companies to offer the prices they charge internationally in the US, often shorthanded as Most Favored Nation (MFN), is getting broad attention because of its significant implications. But while much of the coverage focuses on White House antics, the Pink Sheet has the forethought and global resources to look deeper at the potential impact, particularly in Europe. A trio of recent stories examined how MNF could be a 'game changer' for access, unpacked how difficult higher spending would be to achieve, and considered whether collective procurement could offer a stout defense.
• Notable Theme (Regulatory): In a display of political authority over the public health apparatus, HHS Secretary Kennedy bypassed the CDC and Advisory Committee on Immunization Practices in changing or eliminating some COVID vaccine recommendations. This should put vaccine sponsors on alert that standard processes involving ACIP making recommendations for use following FDA approval may no longer be followed for other types of vaccines.

EDITORIAL CONTENTS (incl. Podcasts, Webinars)

• Notable Podcast: Drug Fix: A New Director For US FDA’s Biologics Center, Guidance Production Slowdowns
• Notable Webinar: ASCO 2025: Key Insights & Innovations (June 17, 2025)
• Notable Webinar: Turbulent Seas: 2025 World Preview (July 1, 2025)

DEALS & FINANCING (incl. M&As, Licensing, Financing)

• Notable M&A: Lilly to Acquire SiteOne Therapeutics for up to $1B
• Notable Licensing: Pfizer Enters into Exclusive $6.15B Licensing Agreement with 3SBio for SSGJ-707 ($1.35B upfront)
• Notable Financing: GlycoEra Gets $130M in Series B Round

KEY R&D EVENTS (incl. Top-line Readouts, Analyst Commentary, Approval/CRL)

• Notable Analysis: Daiichi Sankyo | Enhertu | HER2+ Breast Cancer (Approved): “Significant milestone for AstraZeneca and Daiichi Sankyo as Enhertu demonstrates benefit for the first time in early-stage breast cancer patients…”
• Notable Analysis: Cingulate | CTx-1301 | ADAH (Phase 3): “Positive data from the prematurely terminated Phase III trial assessing CTx-1301 in ADHD bode well for upcoming NDA filing…”
• Notable Analysis: Regeneron | Itepekimab | COPD (Phase 3): “Mixed results from the leading IL-33 inhibitor, itepekimab, have stirred mixed reactions in the COPD market…”

RESEARCH REPORTS (incl. Forecast, Thought Leadership, KOL Interview)

• Notable Report: Annual Completed Clinical Trials Report
• Notable Report: Dealmaking Quarterly Statistics, Q1 2025
• Notable Report: Financing Quarterly Statistics, Q1 2025
• Notable Report: Under Pressure: The State of Biopharma in Q1 2025
• Notable Report: Post-AAN 2025 Conference Report
• Notable Report: ASCO 2025 Weekend Update
• Notable Report: The Methodology Trilogy: How to Forecast like a King
• Notable Report: Patient-based Forecast: Multiple Myeloma
• Notable Report: Epidemiology Forecast: Chronic Lymphocytic Leukemia (CLL)
• Notable Report: Wet AMD KOL Interview – US, South #1
• Notable Report: Epilepsy KOL Interview – France
• Notable Report: Ovarian Cancer KOL Interview – US, Northeast